Signature of TL1A (TNFSF15) signaling pathway
AssigneeCedars-Sinai Medical Center
InventorsKathrin S. Michelsen, Stephan R. Targan
Life of this patent
Estimating the term…
Abstract
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Claims12
A method of treating an inflammatory condition comprising asthma or inflammatory bowel disease in a subject, comprising:
- determining an expression level of one or more cytokines in a sample from the subject;
- and
- treating the inflammatory condition in the subject by administering to the subject an anti-TL1A antibody, provided that the expression level of the one or more cytokines is elevated, as compared to the expression level of the one or more cytokines in an individual that does not have the inflammatory condition;
- wherein the one or more cytokines comprises IL-9.
A method of treating a disease comprising asthma or inflammatory bowel disease in a subject comprising administering to the subject a composition comprising a therapeutically effective dosage of an anti-TL1A antibody, provided that the subject has an elevated expression of IL-9, as compared to the expression of IL-9 in an individual that does not have the disease.
Dependencies are inferred from the claim text.